Curis Announces Genentech's Initiation of Hedgehog Antagonist Phase II Clinical Trial In Metastatic Colorectal Cancer.
Linked as:
Extract
Curis Announces Genentech's Initiation of Hedgehog Antagonist Phase II Clinical Trial In Metastatic Colorectal Cancer.
Trial tests oral administration of GDC-0449 in combination with bevacizumab and a standard chemotherapy regimen
CAMBRIDGE, Mass. -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, today announced that its collaborato...See the full content of this document
Sponsored links
